IGM Biosciences, Inc. (IGMS)
Au 14, 2025 - IGMS was delisted (reason: acquired by Concentra Biosciences)
1.270
-0.030 (-2.31%)
Inactive · Last trade price on Aug 13, 2025
IGM Biosciences Revenue
IGM Biosciences had revenue of $143.62M in the quarter ending June 30, 2025, with 11,353.19% growth. This brings the company's revenue in the last twelve months to $145.05M, up 4,882.82% year-over-year. In the year 2024, IGM Biosciences had annual revenue of $2.68M with 25.77% growth.
Revenue (ttm)
$145.05M
Revenue Growth
+4,882.82%
P/S Ratio
n/a
Revenue / Employee
$9,065,625
Employees
149
Market Cap
n/a
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2.68M | 549.00K | 25.77% |
| Dec 31, 2023 | 2.13M | 1.06M | 99.25% |
| Dec 31, 2022 | 1.07M | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionIGMS News
- 4 months ago - IGM Biosciences Enters into Agreement to Be Acquired by Concentra Biosciences for $1.247 in Cash per Share Plus a Contingent Value Right - GlobeNewsWire
- 10 months ago - IGM Biosciences to cut 73% of workforce as latest pivot fails to pan out - Market Watch
- 10 months ago - IGM Biosciences Provides Strategic Update on Autoimmunity Pipeline Programs - GlobeNewsWire
- 1 year ago - IGM Biosciences Announces Third Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 1 year ago - IGM Biosciences to Present at Three Upcoming Investor Conferences - GlobeNewsWire
- 1 year ago - IGM Biosciences' stock tumbles as analysts weigh in on pivot plan with dismay - Market Watch
- 1 year ago - IGM Biosciences' New Found Focus: Pivots From Cancer To Autoimmune Diseases, Names New CEO - Benzinga
- 1 year ago - IGM Biosciences Stock Drops 27% on ‘Pipeline Transformation' to Autoimmune Diseases - Barrons